| Medical and Health Sciences | 2021-2025 | 290 | JP 2 | 99.94 |
| Surgery | Lifetime | 266 | JP 5 | 99.77 |
| Pulmonary and Respiratory Medicine | Lifetime | 304 | JP 7 | 99.62 |
| Oncology | Lifetime | 541 | JP 17 | 99.00 |
| Gastroenterology | Lifetime | 283 | JP 15 | 96.05 |
| Hepatology | Lifetime | 766 | JP 52 | 85.81 |
| Surgery | 2021-2025 | 17 | JP 1 | 99.90 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 82 | JP 5 | 99.56 |
| Oncology | 2021-2025 | 205 | JP 6 | 98.40 |
| Cancer Research | 2021-2025 | 425 | JP 5 | 67.98 |
| Gastric Cancer Management and Outcomes | Lifetime | 45 | JP 9 | 99.79 |
| Metastasis and carcinoma case studies | Lifetime | 14 | JP 9 | 99.66 |
| Esophageal and GI Pathology | Lifetime | 36 | JP 2 | 99.75 |
| Esophageal Cancer Research and Treatment | Lifetime | 35 | JP 3 | 99.65 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 48 | JP 12 | 99.60 |
| Colorectal Cancer Surgical Treatments | Lifetime | 164 | JP 11 | 98.97 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 414 | JP 47 | 98.92 |
| Colorectal and Anal Carcinomas | Lifetime | 234 | JP 15 | 98.30 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 709 | JP 79 | 98.22 |
| Cancer Cells and Metastasis | Lifetime | 807 | JP 46 | 96.93 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 268 | JP 54 | 94.83 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 830 | JP 181 | 97.07 |
| Multiple and Secondary Primary Cancers | Lifetime | 398 | JP 16 | 96.11 |
| COVID-19 and healthcare impacts | Lifetime | 913 | JP 14 | 92.10 |
| Abdominal vascular conditions and treatments | Lifetime | 707 | JP 53 | 89.65 |
| Esophageal and GI Pathology | 2021-2025 | 1 | JP 1 | 99.91 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 3 | JP 2 | 99.86 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 11 | JP 3 | 99.86 |
| Metastasis and carcinoma case studies | 2021-2025 | 34 | JP 10 | 97.24 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 201 | JP 18 | 98.08 |
| Colorectal Cancer Surgical Treatments | 2021-2025 | 105 | JP 10 | 97.41 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 64 | JP 13 | 97.66 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 271 | JP 22 | 97.05 |
| COVID-19 and healthcare impacts | 2021-2025 | 560 | JP 15 | 92.36 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 870 | JP 9 | 93.40 |
| Surgical site infection prevention | 2021-2025 | 116 | JP 4 | 89.19 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 237 | JP 32 | 88.00 |
| Surgical Simulation and Training | 2021-2025 | 362 | JP 21 | 89.22 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 695 | JP 143 | 90.32 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 827 | JP 127 | 89.20 |
| Colorectal and Anal Carcinomas | 2021-2025 | 731 | JP 60 | 85.29 |
| Enhanced Recovery After Surgery | 2021-2025 | 382 | JP 11 | 79.09 |
| Diverticular Disease and Complications | 2021-2025 | 805 | JP 23 | 73.35 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 652 | JP 25 | 73.10 |
| Minimally Invasive Surgical Techniques | 2021-2025 | 902 | JP 65 | 42.18 |
| Hospital Admissions and Outcomes | 2021-2025 | 736 | JP 30 | 38.51 |